Pacific Biosciences Company Insiders
PACB Stock | USD 1.30 0.04 3.17% |
Pacific Biosciences' insiders are aggressively selling. The analysis of insiders' sentiment of trading Pacific Biosciences of stock suggests that all insiders are panicking at this time. Pacific Biosciences employs about 575 people. The company is managed by 13 executives with a total tenure of roughly 1342 years, averaging almost 103.0 years of service per executive, having 44.23 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-02-18 | Michele Farmer | Disposed 24349 @ 1.88 | View | ||
2025-01-10 | Oene Mark Van | Disposed 34405 @ 2.03 | View | ||
2024-08-19 | Jeff Eidel | Disposed 26760 @ 1.59 | View | ||
2024-08-16 | Oene Mark Van | Disposed 38011 @ 1.66 | View | ||
2024-05-20 | Michele Farmer | Disposed 5275 @ 2.03 | View |
Monitoring Pacific Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Pacific |
Pacific Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.1209) % which means that it has lost $0.1209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.513) %, meaning that it created substantial loss on money invested by shareholders. Pacific Biosciences' management efficiency ratios could be used to measure how well Pacific Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.59. In addition to that, Return On Capital Employed is expected to decline to -0.31. At present, Pacific Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 803 M, whereas Other Assets are forecasted to decline to 1.09.The current year's Common Stock Shares Outstanding is expected to grow to about 302.8 M, whereas Net Loss is projected to grow to (268.7 M).
Pacific Biosciences Workforce Comparison
Pacific Biosciences of is regarded second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,540. Pacific Biosciences totals roughly 575 in number of employees claiming about 23% of equities under Health Care industry.
Pacific Biosciences Profit Margins
The company has Profit Margin (PM) of (2.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.28) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.28.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.28 | 0.2421 |
|
|
Pacific Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacific Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacific Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pacific Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pacific Biosciences Notable Stakeholders
A Pacific Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pacific Biosciences often face trade-offs trying to please all of them. Pacific Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pacific Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christian MBA | CEO, President | Profile | |
Brett JD | General Secretary | Profile | |
Stephen Turner | CoFounder CTO | Profile | |
Susan Kim | Chief Officer | Profile | |
Jeff Eidel | Chief Officer | Profile | |
Denis Zaccarin | Senior Development | Profile | |
Michele CPA | VP Officer | Profile | |
Mike Goloubef | Senior Quality | Profile | |
Mark Oene | Chief Officer | Profile | |
Jonas Korlach | Chief Officer | Profile | |
Trevin Rard | Head Relations | Profile | |
David Ruggiero | Global Service | Profile | |
Natalie Welch | Chief Officer | Profile |
About Pacific Biosciences Management Performance
The success or failure of an entity such as Pacific Biosciences often depends on how effective the management is. Pacific Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pacific management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pacific management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.56) | (0.59) | |
Return On Capital Employed | (0.30) | (0.31) | |
Return On Assets | (0.25) | (0.26) | |
Return On Equity | (0.61) | (0.64) |
Please note, the presentation of Pacific Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pacific Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pacific Biosciences' management manipulating its earnings.
Pacific Biosciences Workforce Analysis
Traditionally, organizations such as Pacific Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pacific Biosciences within its industry.Pacific Biosciences Manpower Efficiency
Return on Pacific Biosciences Manpower
Revenue Per Employee | 267.9K | |
Revenue Per Executive | 11.8M | |
Net Loss Per Employee | 538.9K | |
Net Loss Per Executive | 23.8M | |
Working Capital Per Employee | 746.8K | |
Working Capital Per Executive | 33M |
Complementary Tools for Pacific Stock analysis
When running Pacific Biosciences' price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |